Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases

Advances in Therapy - United States
doi 10.1007/s12325-019-01037-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comment On: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”

Advances in Therapy
MedicinePharmacology
2020English

Comparison of Adherence and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies: A Retrospective Administrative Claims Analysis

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2011English

Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Complementary and Alternative Therapies for Inflammatory Bowel Diseases in Children

Medicina fluminensis
2016English

Dental Morbidities, Smoking, Oral Hygiene, and Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2016English

Medication Adherence and Persistence in Patients With Autoimmune Rheumatic Diseases: A Narrative Review

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2018English

Review Article: Novel Oral-Targeted Therapies in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Immunology and Therapeutic Potential of Antiadhesion Molecule Therapy in Inflammatory Bowel Disease

American Journal of Physiology - Gastrointestinal and Liver Physiology
HepatologyPhysiologyGastroenterology
2005English

Pgi42 - Non-Persistence With Immunosuppresant, Anti-Tumor Necrosis Factor, and Anti-Integrin Agents in Patients With Inflammatory Bowel Disease: A Retrospective Claims Data Analysis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy